

Sunday, 8 November 2026: 10:30-12:30

(0215-0226) Systemic Sclerosis & Related Disorders - Treatment Poster A

(0224) Proton pump inhibitor use and long-term outcomes in systemic sclerosis: a real-life analysis from the EUSTAR database

Francesco Bonomi, MD – Azienda Ospedaliera Universitaria Careggi

(0227-0252) Systemic Sclerosis & Related Disorders - Diagnosis, Manifestations, & Outcomes Poster A

(0234) Evidence-based predictors of systemic sclerosis-interstitial lung disease patients: the EUSTAR-PPFstudy (CP number 148)

Corrado Campochiaro, MD – Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University

(0238) Improvement of nailfold capillaroscopy pattern over time is associated with less disease progression in patients with systemic sclerosis: a EUSTAR study

Carina Mihai, MD;PhD – University Hospital Zurich, University of Zurich

(0241) Prediction of future significant organ involvement in very early and mild systemic sclerosis: a European Scleroderma Trials and Research Group analysis

Madeleine Venables, MBBS, FRACP – Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich; The LOOP Zurich; Department of Rheumatology, St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia

Monday, 9 November 2026: 10:30-12:30

(1172-1182) Systemic Sclerosis & Related Disorders - Treatment Poster B

(1173) Characteristics of Patients Receiving Nintedanib: A Real-World SSc-ILD Cohort Study in the EUSTAR Registry

Madelon C. Vonk, MD, PhD – Department of Rheumatology, Radboud University Medical Center

(1183-1208) Systemic Sclerosis & Related Disorders - Diagnosis, Manifestations, & Outcomes

(1184) Clinical determinants, incidence, and features of interstitial lung disease in anticentromere-positive limited cutaneous systemic sclerosis from the EUSTAR cohort

Antonio Tonutti, Dr – Department of Biomedical Sciences, Humanitas University; Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital

(1206) Time of ILD onset does not impact on the progression and prognosis of interstitial lung disease in systemic sclerosis: results of a EUSTAR cohort analysis (CP196)

Maria Iacovantuono, MD – Rheumatology, Allergology and Clinical immunology, Policlinico Tor Vergata, Rome, Italy

Tuesday, 10 November 2026: 10:30-12:30

(2152-2163) Systemic Sclerosis & Related Disorders - Treatment Poster C

(2160) Impact of age and sex on drugs prescription and effectiveness in systemic sclerosis - an EUSTAR longitudinal analysis

Maria Iacovantuono, MD – Rheumatology, Allergology and Clinical Immunology, Tor Vergata University

(2164-2191) Systemic Sclerosis & Related Disorders - Diagnosis, Manifestations, & Outcomes Poster C

(2180) Persistent Systemic Inflammation Defines a Distinct High-Risk Phenotype in Systemic Sclerosis: Insights from the EUSTAR PERSISTS Study (PERsistent Systemic Inflammation in SysTemic Sclerosis)

Cristiana Sieiro Santos, MD, PhD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

(2228-2283) Systemic Lupus Erythematosus - Diagnosis, Manifestations, & Outcomes Poster C

(2262) New-onset gastrointestinal involvement in systemic sclerosis: incidence across disease-duration windows, clinical predictors and prognostic implications from the EUSTAR cohort

Silvia Bellando Randone, MD;PhD – University of Florence